Note dell’episodio
Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs consider the potential changes that the midterm election rout by Democrats could create for the US Food and Drug Administration in the short-term as agency officials await confirmation of a new commissioner and a new funding bill (1:02), as well as longer-term when the user fee package (14:12) and other issues like vaccines and drug pricing could emerge (25:36).
More On These Topics From The Pink Sheet
Democratic Wins In Congress Will Fuel MFN, FDA Oversight, May Advance Bipartisan…

